Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

Youth ages 1 to 18 consumed more calories from UPFs than adults: 61.9% of calories consumed versus 53% for adults.

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Approximately $1.1 billion deployed during Q2 2025, including the acquisition of Care REIT and entry into the UK care home market. Post-Acquisition Investments-- Nearly $220 million of investments ...

Eli Lilly reported its GLP-1 pill helped patients lose 12.4% body weight in trials, less than Novo Nordisk's Wegovy. Lilly ...

Chai Discovery, a company that builds frontier artificial intelligence models to predict and reprogram interactions between ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.

Eli Lilly and Company LLY reported second-quarter 2025 adjusted earnings per share (“EPS”) of $6.31, which beat the Zacks ...